Discover and read the best of Twitter Threads about #hyperkalaemia
Most recents (4)
1a) Welcome to one of our favorite events on the @academiccme #accredited #tweetorial feeds: a takeover of our programming from @GoggleDocs! The focus of this tweetorial is data from #ADA2022 on #SGLT2i beyond cardiac disease. Our expert author is @GoggleDocs' @drpatrickholmes. 
1b) Check out our other #ADA2022 recap #tweetorial by new @GoggleDocs family member @Ines_VFonseca who focused on the cardiac data presented: ckd-ce.com/dkd13_ada22a/
2) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an educational grant from the Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company. It is intended for healthcare professionals.
1) Welcome to a new #accredited #tweetorial on Cardiorenal Disease in T2D & the Impact of Blocking the MR in Patients w/DKD, another CE/#CME program by one of the @GoggleDocs, this time our friend @AmarPut, Diabetes & Endocrine Consultant in the West Midlands 🇬🇧. #CaReMe #FOAMed
2) This program is supported by an educational grant from Bayer & is intended for #healthcare providers. Author disclosures can be found at ckd-ce.com/disclosures/. Prior programs, still available for CE/#CME credit, are at ckd-ce.com. CE/#CME credit 🇬🇧🇪🇺🇨🇦🇺🇸
3) So first – the ‘triple threat’ . . . We know of the link between the 🫀 and the kidneys and the ‘#cardiorenal’ syndrome, but what about in the setting of #diabetes?
1) Welcome to a new #accredited #tweetorial on currently available treatments for mineralocorticoid receptor (MR) antagonism (#MRA), the differences among them, and how these differences impact on treatment of cardio-reno-metabolic diseases #CaReMe #FOAMed
2) Our expert author is Dr. Patrick Holmes MB BS, MSc, DipTher, MRCGP (@drpatrickholmes), a GP Partner at St. George’s Medical Practice, Darlington for 23 years. He is a Trustee for the Primary Care Diabetes Society and is Associate Editor for Diabetic Medicine @diabeticmed.
3) This program is supported by an educational grant from Bayer & is intended for #healthcare providers. Author disclosures can be found at ckd-ce.com/disclosures/. Prior programs, still available for CE/#CME credit, are at ckd-ce.com. CE/#CME credit 🇬🇧🇪🇺🇨🇦🇺🇸
1/
Hyperkalaemia treatment
KDIGO have just published their conference conclusions on managing acute #hyperkalaemia so I run through some learning points, some criticisms and the bits I’m not sure about as a renal reg.
#medtwitter #nephpearls #meded
Hyperkalaemia treatment
KDIGO have just published their conference conclusions on managing acute #hyperkalaemia so I run through some learning points, some criticisms and the bits I’m not sure about as a renal reg.
#medtwitter #nephpearls #meded
2/
Before we start - why do we care?
Because hyperkalaemia associates with a large increase in risk of death in the next 24 hours.
☠️ mortality not necessarily caused by the hyperkalaemia itself, but can indicate that something bad is happening
ncbi.nlm.nih.gov/m/pubmed/19546…
Before we start - why do we care?
Because hyperkalaemia associates with a large increase in risk of death in the next 24 hours.
☠️ mortality not necessarily caused by the hyperkalaemia itself, but can indicate that something bad is happening
ncbi.nlm.nih.gov/m/pubmed/19546…
3/
So, the KDIGO conference paper.
Firstly, no one can even agree on the definition of hyperK. What’s up with the Swiss? 4.5mmol/l as the upper limit of normal? Compare this with some values used in research papers.....!
So, the KDIGO conference paper.
Firstly, no one can even agree on the definition of hyperK. What’s up with the Swiss? 4.5mmol/l as the upper limit of normal? Compare this with some values used in research papers.....!
